scholarly article | Q13442814 |
P356 | DOI | 10.1017/S1461145714000029 |
P8608 | Fatcat ID | release_o5gv3nvozzbote3htgkwu4qoti |
P698 | PubMed publication ID | 24485144 |
P5875 | ResearchGate publication ID | 260022619 |
P50 | author | María Rodríguez-Muñoz | Q42872732 |
Javier Burgueno | Q114780783 | ||
Daniel Zamanillo | Q122981817 | ||
P2093 | author name string | Javier Garzón | |
Pilar Sánchez-Blázquez | |||
Raquel Herrero-Labrador | |||
P2860 | cites work | Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins | Q21223665 |
What causes the onset of psychosis? | Q22251464 | ||
Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice | Q28184848 | ||
CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
Antagonism of NMDA receptors by sigma receptor ligands attenuates chemical ischemia-induced neuronal death in vitro | Q28215676 | ||
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia | Q28240120 | ||
Causal association between cannabis and psychosis: examination of the evidence | Q28241735 | ||
Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival | Q28255981 | ||
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial | Q28286363 | ||
Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization | Q28301079 | ||
sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures | Q28369929 | ||
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia | Q28510751 | ||
Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics | Q29011855 | ||
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 | ||
Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BiP) interactions | Q30646785 | ||
Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding | Q33754837 | ||
Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells | Q33923685 | ||
Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization | Q34260033 | ||
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). | Q34287318 | ||
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity | Q34691684 | ||
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders | Q34795242 | ||
Risk for schizophrenia--broadening the concepts, pushing back the boundaries | Q36187809 | ||
NMDA receptors and schizophrenia. | Q36650010 | ||
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions | Q36756365 | ||
Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment | Q36899309 | ||
Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats | Q36980744 | ||
Is the histidine triad nucleotide-binding protein 1 (HINT1) gene a candidate for schizophrenia? | Q37312173 | ||
HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity | Q37364657 | ||
Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons | Q37444391 | ||
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia | Q37583070 | ||
The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia | Q37872844 | ||
Sigma-1 receptors: potential targets for the treatment of substance abuse | Q37979827 | ||
Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. | Q38037679 | ||
Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia | Q38340511 | ||
Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. | Q38340750 | ||
Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor | Q38358854 | ||
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study | Q38362304 | ||
The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. | Q39904357 | ||
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance | Q41070625 | ||
Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in mice | Q41664976 | ||
Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse | Q41949285 | ||
Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine | Q41958365 | ||
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. | Q42670368 | ||
Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. | Q42872711 | ||
Involvement of direct inhibition of NMDA receptors in the effects of sigma-receptor ligands on glutamate neurotoxicity in vitro | Q43506948 | ||
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia | Q44167706 | ||
The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation | Q44348688 | ||
Testing hypotheses about the relationship between cannabis use and psychosis | Q44487800 | ||
N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors | Q44728971 | ||
Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor | Q45157391 | ||
Characterization of the cocaine binding site on the sigma-1 receptor | Q46151664 | ||
Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity | Q46813276 | ||
Sigma receptors in schizophrenic cerebral cortices | Q48429016 | ||
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. | Q51909816 | ||
Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users | Q57403275 | ||
Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia | Q67913940 | ||
Distinct neuroprotective profiles for sigma ligands against N-methyl-D-aspartate (NMDA), and hypoxia-mediated neurotoxicity in neuronal culture toxicity studies | Q72347007 | ||
Supportive evidence for the association between the Gln2Pro polymorphism in the SIGMAR1 gene and schizophrenia in the Japanese population: a case-control study and an updated meta-analysis | Q84594757 | ||
P433 | issue | 12 | |
P921 | main subject | CNR2 | Q17907844 |
psychosis | Q170082 | ||
cannabinoid receptor | Q421237 | ||
cannabinoids | Q422936 | ||
P304 | page(s) | 1943-1955 | |
P577 | publication date | 2014-01-31 | |
P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
P1476 | title | The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. | |
P478 | volume | 17 |
Q58732614 | Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor |
Q47299109 | Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. |
Q58851764 | Cocaine Blocks Effects of Hunger Hormone, Ghrelin, Via Interaction with Neuronal Sigma-1 Receptors |
Q53443172 | Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice. |
Q60306762 | Dipentylammonium Binds to the Sigma-1 Receptor and Protects Against Glutamate Toxicity, Attenuates Dopamine Toxicity and Potentiates Neurite Outgrowth in Various Cultured Cell Lines |
Q42317501 | Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction |
Q55340475 | Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. |
Q52318138 | Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process. |
Q41572995 | Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine |
Q64889678 | Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels. |
Q90263450 | Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases |
Q38896666 | Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain |
Q47284001 | Schizophrenia and depression, two poles of endocannabinoid system deregulation |
Q54977290 | Sigma 1 Receptor Antagonists Inhibit Manic-like Behaviors in Two Congenital Strains of Mice. |
Q39158236 | Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics |
Q53647635 | Sigma-1 Receptor and Pain. |
Q41289215 | Sigma-1 and N-Methyl-d-Aspartate Receptors: A Partnership with Beneficial Outcomes |
Q38262682 | The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders |
Q38639528 | The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. |
Q34675713 | The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. |
Q43195386 | The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control |
Search more.